Why Vaxart Stock Is Skyrocketing Today

This article was originally published on this site

© Provided by The Motley Fool Why Vaxart Stock Is Skyrocketing Today

What happened

Shares of Vaxart (NASDAQ: VXRT) were skyrocketing 21.4% higher as of 11:22 a.m. EST on Thursday. The big gains came after the drugmaker announced promising additional data from a preclinical study of its experimental oral COVID-19 vaccine.

So what

Vaxart reported a significant reduction in lung viral loads for hamsters that received two doses of its oral vaccines and were exposed to SARS-CoV-2, the coronavirus that causes COVID-19, compared to non-vaccinated hamsters. The company previously announced results from the preclinical study that showed hamsters that received two doses of its oral vaccine candidate didn’t experience systemic weight loss while unvaccinated animals lost around 9% of their total weight.

© Getty Images Hamster being held by gloved hands with a stethoscope on its chest

Vaxart CEO Andrei Floroiu understandably praised the latest results, stating, “These additional data provide further evidence supporting the efficacy potential of our oral COVID-19 vaccine candidate.” He also noted, “In addition, we believe that our room-temperature-stable oral tablet vaccine would be a more convenient, more practical solution to the COVID-19 pandemic as compared to cold-chain dependent injectable vaccines.”

Video: Cramer reacts to Dow futures soaring on news Pfizer vaccine is 90% effective (CNBC)

Cramer reacts to Dow futures soaring on news Pfizer vaccine is 90% effective
What to watch next

Keep in mind that positive preclinical results with animals often don’t translate to similar results in clinical testing with humans. However, Vaxart’s latest news is definitely encouraging. That’s especially the case considering that hamsters are viewed as very good animal models for evaluating experimental COVID-19 vaccines.

Load Error

Now what

An even bigger catalyst for the biotech stock could be only weeks or even days away. Vaxart initiated a phase 1 clinical study of its oral COVID-19 vaccine candidate in October. The company should soon announce the initial results from this trial. If Vaxart’s experimental vaccine works as well in humans as it has in hamsters, the stock could have a lot more room to run.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

SPONSORED:

10 stocks we like better than Vaxart, Inc

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Vaxart, Inc wasn’t one of them! That’s right — they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of October 20, 2020

 

Continue Reading